Evidence map›Paper›PMID 41462102›Full record

ArticleBMC infectious diseases2025

Clinical efficacy and safety of eravacycline for the treatment of enterococcal infections: a subpopulation analysis.

Sean R Van Helden, Ashlan J Kunz Coyne, Sara Alosaimy, Kyle C Molina, S Lena Kang-Birken, Justin Andrade, Madeline A King, Kimberly C Claeys, Athena L V Hobbs, Nicholson B Perkins Iii and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Sean R Van HeldenAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.
Ashlan J Kunz CoyneAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.
Sara AlosaimyAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.
Kyle C MolinaUniversity of Colorado Anschutz School of Medicine, Aurora, CO, USA.
S Lena Kang-BirkenSanta Barbara Cottage Hospital, Santa Barbara, CA, USA.
Justin AndradeTouro College of Pharmacy, The Brooklyn Hospital Center, New York, NY, USA.
Madeline A KingPhiladelphia College of Pharmacy, Saint Joseph's University, Philadelphia, PA, USA.
Kimberly C ClaeysUniversity of Maryland School of Pharmacy, Baltimore, MD, USA.
Athena L V HobbsMethodist University Hospital, Memphis, Tennessee, USA.
Nicholson B Perkins IiiMethodist University Hospital, Memphis, Tennessee, USA.
Jazmin AgeeMethodist University Hospital, Memphis, Tennessee, USA.
Alaina DeKerlegandOur Lady of the Lake Regional Medical Center, Baton Rouge, LA, USA.
Mark BiagiUW Health Swedish American Hospital, Rockford, IL, USA.
Michael P VeveEugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, USA.
Serina TartCape Fear Valley Health, Fayetteville, North Carolina, USA.
Tristan GoreCollege of Pharmacy, University of South Carolina, Columbia, SC, USA.
Bruce M JonesSt. Joseph's/Candler Health System, Savannah, GA, USA.
Benjamin M PullingerCooper University Hospital, Camden, NJ, USA.
Melanie Rae SchrackOur Lady of the Lake Regional Medical Center, Baton Rouge, LA, USA.
Reese CosimiAscension St. Vincent Hospital, Indianapolis, IN, USA.
Shelbye R HerbinJohn D. Dingell VA Medical Center, Detroit, MI, USA.
Chloe JuddAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.
Mohammed Al MusawaAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.
Michael J RybakAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA. m.rybak@wayne.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfections due to Enterococcus faecalis and Enterococcus faecium are common in the hospital setting and carry a high risk for morbidity and mortality. Furthermore, the incidence of drug-resistant phenotypes, such as vancomycin-resistant Enterococci (VRE) and daptomycin non-susceptible strains, is increasing. Eravacycline (ERV) is a novel tetracycline antibiotic approved for the treatment of complicated intra-abdominal infections and possesses a broad spectrum of activity across both Gram-positive and Gram-negative organisms, including VRE, methicillin-resistant Staphylococcus aureus, and carbapenem-resistant Enterobacterales.

methodsWe conducted a subgroup analysis assessing the real-world efficacy and safety of ERV for the treatment of enterococcal infections. Adult patients who received ERV for ≥ 72 h for E. faecalis or E. faecium infections were included. The primary outcome of clinical cure was defined as resolution or improvement of infection-related signs and/or symptoms.

resultsA total of 100 patients were included in the analysis. E. faecalis and E. faecium were present in 44% and 58% of patients, respectively, and 49% of all isolates were VRE. The most prevalent infection types were intra-abdominal, skin/soft tissue, and osteomyelitis, and a majority (80%) of infections were polymicrobial. Clinical cure was achieved in 77% of patients. Thirty-day mortality was 17% and 30-day infection-related mortality was 12%. Thirty-day hospital readmission rate was 14%, and microbiological recurrence occurred in 4% of patients. Treatment-emergent adverse events occurred in 8% of patients, with 2% of patients requiring discontinuation of ERV.

conclusionThis study describes the real-world safety and efficacy of ERV for the treatment of enterococcal infections.

Indexed as

Anti-Bacterial AgentsGram-Positive Bacterial InfectionsTetracyclinesAdultAgedAged, 80 and overEnterococcus faecalisEnterococcus faeciumFemaleHumansMaleMiddle AgedTreatment OutcomeVancomycin-Resistant EnterococciAnti-Bacterial AgentseravacyclineTetracyclinesEnterococcusEnterococcus faecalisEnterococcus faeciumEravacyclineTetracyclineVancomycin-resistant enterococcusVRE

Identifiers

PMID41462102
PMCPMC12751535

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.